Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2018-04-24 Report Publication Anno…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
2018年第一季度报告披露提示性公告
Report Publication Announcement Classification · 100% confidence The document is a short announcement (432 characters) indicating that the company's 2018 first quarter report has been approved and will be disclosed on a regulatory website. It does not contain the actual financial data or detailed report content but rather informs investors about the availability of the report. According to the 'MENU VS MEAL' rule, such a brief notice about report disclosure is classified as a Report Publication Announcement (RPA).
2018-04-24 Chinese
2017年度控股股东及其他关联方资金占用情况汇总表
Audit Report / Information Classification · 95% confidence The document is a detailed summary table of funds occupied by controlling shareholders and related parties for the year 2017, including accounting categories, amounts at the beginning and end of the year, and explanations of the nature of the funds. It includes signatures of legal representatives and accounting officers, indicating it is an official financial disclosure related to internal or regulatory reporting. The content focuses on related party transactions and fund occupation, which is typical of audit or regulatory disclosures rather than a full annual report or earnings release. There is no indication that this is a full annual report (10-K) or an earnings release (ER). It is not a management change announcement, call transcript, or capital update. The document is not a proxy statement or voting result. It is a standalone report on related party fund occupation, which fits best under Audit Report / Information (AR). The document length is sufficient to be a report, not just an announcement. Therefore, the classification is AR with high confidence. FY 2017
2018-04-11 Chinese
关于举行2017年度网上业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is a short announcement about the company holding an online earnings presentation (业绩说明会) for the 2017 annual results. It references that the full 2017 annual report has already been published on the official disclosure website. The document invites investors to participate in the online performance explanation meeting scheduled for April 13, 2018. The document length is only 547 characters, indicating it is an announcement rather than the full report or transcript. This fits the definition of an Investor Presentation (IP) announcement, specifically an invitation to a performance explanation meeting. It is not the full Annual Report (10-K) or a Call Transcript (CT). Therefore, the best classification is Investor Presentation (IP).
2018-04-11 Chinese
2018年股票期权激励计划（草案）摘要
Capital/Financing Update Classification · 95% confidence The document is a detailed summary draft of a 2018 stock option incentive plan for Betta Pharmaceuticals Co., Ltd. It includes extensive information about the plan's purpose, management structure, eligibility criteria, stock option quantities, allocation, exercise price, exercise conditions, adjustment methods, and accounting treatment. The content is focused on the company's stock option incentive plan, which is a form of equity compensation and capital/financing activity. It is not a financial report, earnings release, or regulatory filing. The document is lengthy (15,000 characters) and contains substantive details about the stock option plan rather than just an announcement or summary. Therefore, the most appropriate classification is Capital/Financing Update (CAP), as it relates to company fundraising and capital structure changes through stock option grants.
2018-04-09 Chinese
2018年股票期权激励计划（草案）
Capital/Financing Update Classification · 95% confidence The document is titled '2018 年股票期权激励计划（草案）' which translates to '2018 Stock Option Incentive Plan (Draft)'. It details the company's stock option incentive plan, including the purpose, management structure, eligibility, stock option quantities, allocation, exercise price, exercise conditions, and other related governance and procedural information. The document is a comprehensive plan draft for stock option incentives, which is a form of capital/financing update related to the company's equity compensation and capital structure. It is not an annual report, earnings release, or regulatory filing, nor is it a voting result or management change announcement. It is a detailed plan document about capital structure changes and financing incentives. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the plan itself, not just an announcement of a report, so it is not RPA or RNS. Confidence is high due to the clear content and context.
2018-04-09 Chinese
关于以闲置自有资金购买保本型理财产品的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from the company regarding the decision to use idle funds to purchase low-risk, short-term capital-protected financial products. It details the board meeting resolution, investment purpose, risk analysis, and independent directors' opinions. The document is relatively short (1980 characters) and serves as a formal disclosure of a financing-related decision rather than a full financial report or detailed management discussion. It does not contain financial statements or earnings data, nor is it a report publication or certification. The content fits best under Capital/Financing Update (CAP) as it relates to the company's financing activities and capital management decisions.
2018-04-09 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.